Summary
Most claims relate to sildenafil formulations and PAH/ED interchangeability, but the provided FDA label excerpts are only for VIAGRA (erectile dysfunction). As a result, many claims cannot be verified against the supplied prescribing information and several are inconsistent with the label’s indication scope.
Category Scores
Accurate Statements
VIAGRA is indicated for the treatment of erectile dysfunction.
Section 1 INDICATIONS AND USAGE: “VIAGRA is indicated for the treatment of erectile dysfunction.”
Unsupported Statements
Generic Viagra is available because sildenafil’s patents have expired.
No patent-expiration or generic-availability statements are present in the provided label excerpts.
Generic Revatio exists.
The provided label excerpts are for VIAGRA only and do not mention Revatio or its generic availability.
Revatio is sildenafil approved for pulmonary arterial hypertension (PAH).
The provided label excerpts do not include any PAH indication or any Revatio-specific labeling.
Sildenafil for PAH is typically prescribed on an ongoing basis to help manage the condition.
No PAH-related indication, regimen, or chronic/ongoing administration guidance is present in the provided VIAGRA label excerpts.
Dosing of sildenafil for PAH may differ from Viagra because the indication and treatment goals are different.
No PAH dosing guidance is present in the provided label excerpts, so the claim cannot be supported or verified against them.
Generic Viagra and generic Revatio can have the same active ingredient (sildenafil).
The provided label excerpts specify sildenafil citrate for VIAGRA, but do not mention Revatio formulations; active-ingredient overlap with Revatio is not supported by the supplied excerpts.
Generic Viagra and generic Revatio are not automatically interchangeable in practice.
The provided VIAGRA label excerpts do not address interchangeability between VIAGRA and Revatio (or between ED and PAH products).
Interchangeability depends on the patient’s diagnosis (ED vs PAH).
The supplied excerpts are limited to VIAGRA’s ED indication and do not discuss switching/interchangeability criteria based on diagnosis.
Interchangeability depends on the prescribed dose and dosing schedule.
The provided excerpts do include dosing details for VIAGRA, but they do not provide labeling statements about interchangeability decisions.
Interchangeability depends on the formulation received (tablet strength) matching what the prescriber intended.
No label text in the provided excerpts addresses switching/interchangeability based on tablet strength intended by the prescriber.
Switching products should be done under clinician guidance even when both are sildenafil.
The provided VIAGRA label excerpts do not contain statements about switching between different sildenafil products.
Revatio is used for PAH.
No Revatio or PAH usage is included in the provided VIAGRA label excerpts.
Even when the active ingredient overlaps, ED and PAH are different conditions with different prescribing standards, which affects how the medication is chosen and monitored.
The provided excerpts do not include any PAH prescribing/monitoring standards or statements comparing ED vs PAH prescribing.
Patients can look at the label to confirm the indication (PAH vs ED).
The provided label excerpts only include an ED indication for VIAGRA; PAH indication labeling is not provided.
Patients can look at the label to confirm the brand/generic name and strength.
The provided VIAGRA excerpts do not support patient instructions about confirming brand/generic name and strength.
Patients can look at the label to confirm the dosing instructions written by the prescriber.
The provided VIAGRA excerpts provide dosing instructions but do not include statements that patients should confirm prescriber-written dosing instructions via the label.
Contradictions
Low
AI Statement
Revatio is sildenafil approved for pulmonary arterial hypertension (PAH).
Label Reference
Section 1 INDICATIONS AND USAGE for VIAGRA only (ED indication provided in excerpts).
Important Omissions
For claims about dosing differences and ongoing PAH use, the supplied VIAGRA label excerpts do not include any PAH/Revatio dosing or administration information needed to evaluate those claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only clearly supported claim concerns VIAGRA’s ED indication. Many other claims cannot be verified from the supplied VIAGRA label excerpts and relate to PAH/Revatio, which are outside the provided labeling scope.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Most claims (Revatio/PAH, interchangeability between products, and patent/generic availability) are not supported by the provided VIAGRA prescribing information excerpts and cannot be verified against them.
Suggested Improvement
Limit evaluation and wording to the provided VIAGRA label content (ED indication and associated dosing/precautions/interactions). Exclude or qualify claims about Revatio, PAH dosing, and product interchangeability unless the corresponding FDA-approved Revatio label text is supplied.